Journal
CANCER CELL
Volume 37, Issue 4, Pages 485-495Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2020.03.012
Keywords
-
Categories
Funding
- Manchester CRUK Centre Award, United Kingdom [A25254]
- CRUK Manchester Experimental Cancer Medicines Centre, United Kingdom [A25146]
- CRUK Lung Cancer Centre of Excellence, United Kingdom [A29420]
- Manchester NIHR Biomedical Research Centre, United Kingdom
- AstraZeneca, United Kingdom
- Astex Pharmaceuticals, United States
- Bioven, United Kindom
- Amgen, United States
- Carrick Therapeutics, Republic of Ireland
- Merck AG, Germany
- Taiho Oncology, Japan
- Biolidics Limited, Singapore
- Angle PLC, United Kingdom
- Menarini Diagnostics, Italy
- GSK, United Kingdom
- Bayer, Germany
- Boehringer Ingelheim, Germany
- Roche, Switzerland
- BMS, United States
- Novartis, Switzerland
- Celgene, United States
- Thermo Fisher, United States
- [A27412]
Ask authors/readers for more resources
Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations within an individual's tumor. Patients' responses to targeted therapies are commonly followed by treatment resistance. Here, we survey liquid biopsies as alternatives to tumor biopsies to assess predictive and therapy response biomarkers. We examine the potential of liquid biopsies to meet the challenges of minimal residual disease monitoring after curative intent treatment for earlier detection of disease recurrence. We focus on blood, the most commonly collected minimally invasive clinical sample, and on the two most widely studied assays, circulating tumor DNA and circulating tumor cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available